ZYUS Life Sciences Announces Closing of Debt Financing

Executive Summary

• ZYUS Life Sciences Corp. closed a C$0.5 million unsecured promissory note debt financing on March 5, 2026.
• The note bears 12% annual interest, matures on August 5, 2026, and is payable in full (including accrued interest) at maturity; it is non‑convertible and may be prepaid without penalty.
• Proceeds will be used for general working capital purposes.

Key Details

• Financing Structure: Unsecured promissory note (“Unsecured Note”) issued to an arm’s‑length third‑party lender.
• Principal Amount: C$0.5 million.
• Interest Rate: 12% per annum, simple interest calculated from the issuance date.
• Maturity Date: August 5, 2026.
• Payment Terms: Interest payable at maturity; principal and accrued interest may be prepaid at any time without penalty or premium.
• Conversion Rights: The Unsecured Note is not convertible into equity.
• Use of Proceeds: General working capital purposes.
• Regulatory Notice: Subject to notice requirement under TSX Venture Exchange rules.

Notable Quotes

(No executive quotes were included in the release.)